Tirzepatide

What it is

Tirzepatide is a once-weekly injectable peptide that mimics two gut hormones at the same time, GLP-1 and GIP, instead of just one like older drugs such as semaglutide (Ozempic/Wegovy). Both hormones normally get released after eating; activating both together tells the pancreas to release more insulin only when blood sugar is high, tells the liver to stop overproducing sugar, slows how fast food leaves the stomach, and turns down appetite signals in the brain. The result is lower blood sugar (its first FDA approval, as Mounjaro, for type 2 diabetes) and significant appetite reduction and weight loss (its second approval, as Zepbound, for chronic weight management and for obstructive sleep apnea with obesity). It only needs weekly dosing because a fatty-acid side chain lets it bind reversibly to albumin, the most common blood protein, which acts like a slow-release depot and keeps it active for days instead of hours.

Dose ranges

Study-backed ranges carry a source you can open. Community ranges are widely reported but not clinically established - treat them as what people do, not as advice.

Reconstitution & storage

No FDA-approved tirzepatide vial exists for patient reconstitution - Mounjaro and Zepbound ship as ready-to-use pens/vials already in solution, never as a powder patients mix themselves. These figures reflect compounded/research-vial vendor and community practice only, not an approved product. Commonly documented ratios: 5 mg vial + 1 mL bacteriostatic water, 10 mg + 2 mL, 15 mg + 3 mL - all landing near 5 mg/mL. Reconstituted-with-bacteriostatic-water solution is commonly reported stable refrigerated up to 28 days; plain sterile (non-bacteriostatic) water is commonly limited to 24 hours. Always use bacteriostatic water made for injection, never tap or plain distilled water.

Interactions & cautions

Contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on dose- and duration-dependent thyroid C-cell tumors seen in rodents (human relevance unknown) - per the Mounjaro and Zepbound labels. Can cause acute pancreatitis, including fatal or hemorrhagic/necrotizing cases; discontinue and seek care for severe or persistent abdominal pain. Raises hypoglycemia risk when combined with insulin or an insulin secretagogue such as a sulfonylurea - the Zepbound label reports hypoglycemia in 10.3% of patients also taking a sulfonylurea versus 2.1% not taking one, and a lower dose of the other drug is often needed. Delays gastric emptying, which can slow or reduce absorption of other oral medications; the label specifically tells patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. Also linked to gallbladder disease (cholelithiasis/cholecystitis) and acute kidney injury risk from dehydration during severe GI side effects (nausea, vomiting, diarrhea).

Questions people ask

Sources

1. [1]MOUNJARO (tirzepatide) injection, solution - FDA Prescribing InformationlabelFDA-approved type 2 diabetes dosing: 2.5 mg/week starting dose (4 weeks, not for glycemic control), titrated in 2.5 mg increments to a 5-15 mg/week adult maintenance range (5-10 mg for ages 10-17); half-life approximately 5 days; contraindicated with personal/family MTC or MEN2 history; mechanism is combined GIP and GLP-1 receptor agonism; warns of pancreatitis and increased hypoglycemia risk with insulin or insulin secretagogues.
2. [2]ZEPBOUND (tirzepatide) injection, solution - FDA Prescribing InformationlabelFDA-approved dosing for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity: 2.5 mg/week for 4 weeks then 2.5 mg increments (at least 4 weeks apart) up to a 15 mg/week maximum; half-life approximately 5-6 days; hypoglycemia occurred in 10.3% of patients also on a sulfonylurea vs 2.1% not on one; delayed gastric emptying can reduce absorption of oral drugs including oral contraceptives, so patients are told to add a barrier method or switch to non-oral contraception for 4 weeks after starting or each dose increase; contraindicated with personal/family MTC or MEN2 history.
3. [3]Tirzepatide - StatPearlsreviewDescribes tirzepatide as a 39-amino-acid synthetic dual GIP/GLP-1 receptor agonist peptide with ~5 day half-life, ~80% bioavailability, ~99% plasma protein binding, and peak levels at 8-72 hours; confirms MTC/MEN2 contraindication and pancreatitis, hypoglycemia, and gallbladder disease as key risks; notes off-label obesity-trial weight loss of 16.5-22.4% over 72 weeks in non-diabetic participants.
4. [4]Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical modelsstudyPreclinical (rat and shrew) study finding tirzepatide's added GIP receptor agonism blocked emesis and reduced a nausea-proxy behavior (kaolin consumption) compared to equipotent semaglutide doses at similar appetite-suppressing effect - animal-model evidence, not a human clinical trial.
5. [5]Mounjaro and refrigeration: Storage, expiration, and morepatient_educationStates Mounjaro pens must be refrigerated at 36-46F (2-8C), may be kept at room temperature up to 86F (30C) for a maximum of 21 days before disposal, should stay in the original carton to protect from light, and must never be frozen.
6. [6]What to Know about Storing Zepbound Safelypatient_educationStates Zepbound pens/vials must be refrigerated at 36-46F (2-8C) or kept at room temperature (not exceeding 86F/30C) for a maximum of 21 days, protected from light in original packaging, never frozen, and not returned to the fridge once warmed to room temperature.
7. [7]Tirzepatide Reconstitution: 5mg + 2mL ChartcommunityDocuments common compounded/research tirzepatide vial reconstitution ratios (5mg+1mL, 10mg+2mL, 15mg+3mL bacteriostatic water, each landing near 5 mg/mL), reports refrigerated stability up to 28 days after reconstitution with bacteriostatic water versus 24 hours with plain sterile water, and explicitly states these research/compounded forms are not FDA-approved.
8. [8]Microdosing Tirzepatide: Chart, Schedule & Pros/ConscommunityDescribes community/off-label microdosing doses of 0.5-2 mg weekly (below the FDA 2.5 mg starting dose) used for side-effect management, sensitive responders, or step-down maintenance, explicitly stating it is not FDA-approved, not in official prescribing guidance, and unsupported by published phase 3 trials.